Abstract:In this review, we assess the current role of single-photon emission computed tomography (SPECT) and positron emission tomography (PET) in the imaging of skeletal metastatic disease from a miscellaneous group of malignancies, including lung, thyroid, and renal carcinomas; multiple myeloma; and neuroendocrine tumors, and consider how recent advances may enhance their effectiveness in this area. Bone scintigraphy using technetium-labeled diphosphonates has long been the mainstay of functional imaging of bony metastases, but is of limited value in myeloma and aggressive osteolytic metastases, and has the limitation of relatively poor specificity. SPECT, as a tomographic imaging technique, produces three-dimensional images of tracer distribution from multiplanar images. Its application to bone scintigrams greatly aids accurate anatomic localization and sensitivity in detection of foci of tracer uptake. SPECT can equally be applied to scintigrams using radiotracers, which are specific for particular groups of tumors, such as somatostatin analogs for neuroendocrine tumors. The advent of combined SPECT/computed tomography (CT) systems has further enhanced the accuracy of SPECT in all these malignancies. PET uses positron-emitting radiotracers and achieves a higher spatial resolution than single-photon imaging. Its high resolution and coverage of the entire body have made it a highly effective technique for the evaluation of skeletal metastatic disease, particularly when combined with CT. (18)F-fluorodeoxyglucose ((18)F-FDG)-PET/CT now forms part of routine staging for many carcinomas, such as non-small-cell lung carcinomas, and may obviate the need for routine staging scintigraphy in these patients. As uptake of the most common PET radiotracer, (18)F-FDG, is dependent on the increased cellular metabolism of most tumors, it may enable earlier detection of metastatic foci than bone scintigraphy, which relies on detecting an osteoblastic response. Another significant advantage of (18)F-FDG-PET is that it can detect soft-tissue components of metastases, which is particularly important in aggressive osteolytic metastases. The effectiveness of (18)F-FDG-PET is limited in slow-growing tumor types, but (18)F-sodium fluoride, a bone radiotracer that can detect early osteoblastic changes, shows promise in this area. Bony metastases from many neuroendocrine tumors can be detected with a high degree of specificity by PET using somatostatin analogs. Other novel and often highly specific radiotracers are under evaluation, which will further enhance the diagnostic capability of PET. The true potential of PET in this group of malignancies is gradually unfolding, although studied series of patients remain generally small and much further evaluation of its role is required.

68Ga-Citrate PET/CT Imaging in the Diagnosis of Skull Base Osteomyelitis and Its Usefulness in the Assessment of Treatment Response

18F-FDG PET imaging for treatment response assessment and management guidance in patients with skull base osteomyelitis

Comparative study of reliability of inflammatory markers over 18-FDG−PET CT scan in monitoring skull base osteomyelitis

The challenging diagnosis and follow-up of skull base osteomyelitis in clinical practice

Response of osteogenic sarcoma to neoadjuvant therapy: evaluated by 18F-FDG-PET

A comprehensive review of skull base osteomyelitis: Diagnostic and therapeutic challenges among various presentations

Dynamic contrast-enhanced MRI parameters and apparent diffusion coefficient as treatment response markers of skull base osteomyelitis: a preliminary study

Could 68 Ga-DOTA-UBI-29-41 Help Identify Chronic Osteomyelitis on PET/CT Images? A Pilot Study

SPECT/CT, PET/CT, and PET/MRI for Response Assessment of Bone Metastases

Skull base osteomyelitis: Comprehensive analysis and a new clinicoradiological classification system

Imaging of Acute and Chronic Skull Base Infection

Application of 68Ga-citrate PET/CT for differentiating periprosthetic joint infection from aseptic loosening after joint replacement surgery

68Ga-DOTATATE PET-CT as a tool for radiation planning and evaluating treatment responses in the clinical management of meningiomas

Prediction and Evaluation of Neoadjuvant Chemotherapy Using the Dual Mechanisms of 99Mtc-Mibi Scintigraphy in Patients with Osteosarcoma

Comparison of diagnostic efficacy between 99mTc-methylene diphosphate SPECT/CT and MRI for bone and joint infections: a multicenter retrospective analysis

68Ga-Pentixafor PET/CT for in-vivo mapping of CXCR4 receptors as potential radiotheranostic targets in soft tissue and bone sarcoma: preliminary results

Diagnostic performance of [68Ga]DOTATATE PET/CT, [18F]FDG PET/CT, MRI of the spine, and whole-body diagnostic CT and MRI in the detection of spinal bone metastases associated with pheochromocytoma and paraganglioma

Musculoskeletal Infection: Role of Molecular Imaging in Diagnosis and Monitoring Treatment Response

Miscellaneous cancers (lung, thyroid, renal cancer, myeloma, and neuroendocrine tumors): role of SPECT and PET in imaging bone metastases

68Ga-Pentixafor PET/CT for In Vivo Imaging of CXCR4 Receptors in Glioma Demonstrating a Potential for Response Assessment to Radiochemotherapy: Preliminary Results

Skull Base Osteomyelitis: A Comprehensive Imaging Review